• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    23andMe Announces 1-for-20 Reverse Stock Split

    10/11/24 8:15:00 AM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ME alert in real time by email

    SUNNYVALE, Calif., Oct. 11, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) (the "Company" or "23andMe"), announced today that the 1-for-20 reverse stock split of the Company's Class A and Class B common stock will become effective as of 12:01 a.m. EST on October 16, 2024 (the "Effective Time").

    As previously disclosed, at the Company's 2024 Annual Meeting of Stockholders, the Company's stockholders voted to approve an amendment to the Company's Certificate of Incorporation (the "Charter Amendment") to combine outstanding shares of Class A common stock and Class B common stock, respectively, into a lesser number of outstanding shares by a ratio of not less than one-for-five and not more than one-for-thirty, with the exact ratio to be set within this range by the Company's Board of Directors (the "Board"). Following such stockholder approval, the Board approved a final reverse stock split ratio of 1-for-20. Accordingly, the Company is effecting the reverse stock split by filing the Charter Amendment with the Secretary of State of the State of Delaware.

    The Company's Class A common stock will begin trading on The Nasdaq Capital Market on a split-adjusted basis when the market opens on October 16, 2024, under a new CUSIP number, 90138Q306.

    As a result of the reverse stock split, each 20 shares of the Company's Class A and Class B common stock issued and outstanding immediately prior to the Effective Time will be automatically combined into one share of Class A common stock and Class B common stock, respectively. The Company will not issue any fractional shares of its Class A or Class B common stock as a result of the reverse stock split. Instead, any fractional shares will be rounded up to the next whole number.

    The same 1-for-20 reverse stock split ratio is being used to effect the reverse stock split of both the Company's Class A and Class B common stock, and accordingly, all stockholders will be affected proportionately. The reverse stock split will reduce the Company's issued and outstanding shares of common stock from approximately 350,292,546 shares of Class A common stock and 166,443,192 shares of Class B common stock to approximately 17,514,628 and 8,322,160 shares, respectively.

    The number of shares of Class A common stock subject to the Company's outstanding restricted stock unit and stock option awards, as well as the relevant exercise price per share with respect to such outstanding stock option awards, will be proportionately adjusted to reflect the reverse stock split. The number of Class A common stock shares authorized and available for issuance under the Company's incentive equity plan and employee stock purchase plan will also be reduced to reflect the reverse stock split, using the same 1-for-20 split ratio.

    A stockholder whose shares are registered directly in their name with our transfer agent, Continental Stock Transfer & Trust Company ("CST"), is considered a holder of record (or the registered stockholder). Registered stockholders who hold shares electronically in book-entry form with CST will not need to take action to receive evidence of their shares of post–reverse stock split Class A common stock or Class B common stock. A stockholder whose shares are held in an account at a brokerage firm, bank, or other similar organization is considered a beneficial owner of shares held in "street name." Banks, brokers, or other nominees will be instructed to effect the reverse stock split for their beneficial holders holding Class A common stock in street name. However, these banks, brokers, or other nominees may have different procedures than registered stockholders for processing the reverse stock split. Stockholders who hold shares of Class A common stock with a bank, broker, or other nominee and who have any questions in this regard are encouraged to contact their banks, brokers, or other nominees.

    Upon the Effective Time, each certificate, if any, representing shares of the Company's common stock immediately prior to the reverse stock split will be deemed to represent the number of full shares of common stock resulting from the reverse stock split. Stockholders holding their shares in book entry form are not required to take any action, as their shares will be adjusted directly by CST.

    About 23andMe

    23andMe is a genetics-led consumer healthcare and therapeutics company empowering a healthier future. For more information, please visit www.23andme.com.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical fact, included or incorporated in this press release are forward-looking statements. The words "believes," "anticipates," "estimates," "plans," "expects," "intends," "may," "could," "should," "potential," "likely," "projects," "predicts," "continue," "will," "schedule," and "would" or, in each case, their negative or other variations or comparable terminology, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are predictions based on 23andMe's current expectations and projections about future events and various assumptions. 23andMe cannot guarantee that it will actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements and you should not place undue reliance on 23andMe's forward-looking statements. These forward-looking statements involve a number of risks, uncertainties (many of which are beyond the control of 23andMe), or other assumptions that may cause actual results or performance to differ materially from those expressed or implied by these forward-looking statements. Among such risks and uncertainties are unexpected developments with respect to the reverse stock split, including, without limitation, future decreases in the price of the Company's Class A common stock whether due to, among other things, the announcement of the reverse stock split, the Company's inability to make its Class A common stock more attractive to a broader range of institutional or other investors, or an inability to increase the stock price in an amount sufficient to satisfy compliance with the Nasdaq's minimum closing bid price requirement for continued listing. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's filings with the Securities and Exchange Commission, including under Item 1A, "Risk Factors" in the Company's most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission, and as revised and updated by the Company's Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The statements made herein are made as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to update them, whether as a result of new information, developments, or otherwise.

    For further information, please contact:

    23andMe

    [email protected]

    [email protected]



    Primary Logo

    Get the next $ME alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ME

    DatePrice TargetRatingAnalyst
    11/29/2022$7.00Buy
    Berenberg
    9/22/2022$6.00Outperform
    Cowen
    2/11/2022$14.00 → $11.00Outperform
    Credit Suisse
    12/20/2021$13.00 → $9.00Neutral
    Citigroup
    11/15/2021$12.00 → $13.00Buy → Neutral
    Citigroup
    11/11/2021$13.00 → $14.00Outperform
    Credit Suisse
    8/17/2021$13.00Outperform
    Credit Suisse
    7/12/2021$14.00Buy
    Citigroup
    More analyst ratings

    $ME
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Berenberg initiated coverage on 23andMe with a new price target

    Berenberg initiated coverage of 23andMe with a rating of Buy and set a new price target of $7.00

    11/29/22 7:24:54 AM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cowen initiated coverage on 23andMe with a new price target

    Cowen initiated coverage of 23andMe with a rating of Outperform and set a new price target of $6.00

    9/22/22 7:20:18 AM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Credit Suisse reiterated coverage on 23andMe Holding with a new price target

    Credit Suisse reiterated coverage of 23andMe Holding with a rating of Outperform and set a new price target of $11.00 from $14.00 previously

    2/11/22 8:14:04 AM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ME
    SEC Filings

    View All

    SEC Form 8-K filed by 23andMe Holding Co.

    8-K - 23andMe Holding Co. (0001804591) (Filer)

    3/28/25 4:09:11 PM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    23andMe Holding Co. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - 23andMe Holding Co. (0001804591) (Filer)

    3/24/25 6:23:28 AM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by 23andMe Holding Co.

    10-Q - 23andMe Holding Co. (0001804591) (Filer)

    2/6/25 4:27:52 PM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ME
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    23andMe Confirms All Potential Buyers Must Agree to Comply With Privacy Policy and Applicable Law

    SAN FRANCISCO, March 26, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. ("23andMe" or the "Company") (NASDAQ:ME), a leading human genetics and biotechnology company, today announced that it has received approvals from the U.S. Bankruptcy Court for the Eastern District of Missouri (the "Court") for its "first day" motions related to 23andMe's voluntary Chapter 11 petitions filed March 23, 2025, including authorization to pay employee wages and benefits and compensate certain vendors and suppliers in the ordinary course for goods and services provided and to enter into the binding term sheet for a $35 million debtor-in-possession financing facility from JMB Capital Partners (the "DIP Facility"

    3/26/25 6:57:42 PM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    23andMe Initiates Voluntary Chapter 11 Process to Maximize Stakeholder Value Through Court-Supervised Sale Process

    Intends to use Proceedings to Conduct a Value-Maximizing Sale Process and Resolve Liabilities Company Expects to Continue Business Operations in the Ordinary Course During Proceedings; Secures Commitment for Approximately $35 Million in DIP Financing to Support Ongoing Operations No Changes to Customer Data Management and Access; Company Remains Committed to Transparency Around Customer Data Privacy; Any Buyer will be Required to Comply with Applicable Law with Respect to Treatment of Customer Data Company Announces Board and Leadership Changes to Support Restructuring and Sale Process SAN FRANCISCO, March 23, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. ("23andMe" or the "Company") (

    3/23/25 11:08:03 PM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    23andMe Launches New Homocysteine (MTHFR-Related) Genetic Report and Accompanying Lab Test

    SAN FRANCISCO, March 21, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME), a leading human genetics company with a mission to help people access, understand, and benefit from the human genome, today released a new report on the genetics of homocysteine levels for 23andMe+ Premium members, as well as a blood test for next steps in further understanding said levels for an additional fee. One of the top 23andMe customer requested reports, it informs users if they are at a higher likelihood of developing slightly elevated homocysteine levels along with actionable lifestyle factors that can reduce their chances. Homocysteine is an amino acid that plays a key role in important process

    3/21/25 7:30:00 AM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ME
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Kvarda Matthew

    3 - 23andMe Holding Co. (0001804591) (Issuer)

    3/26/25 4:38:00 PM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Walper Thomas B.

    3 - 23andMe Holding Co. (0001804591) (Issuer)

    3/26/25 4:35:46 PM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial & Actng Ofcr Selsavage Joseph Anthony covered exercise/tax liability with 5,654 shares, decreasing direct ownership by 6% to 96,468 units (SEC Form 4)

    4 - 23andMe Holding Co. (0001804591) (Issuer)

    2/21/25 5:05:56 PM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ME
    Financials

    Live finance-specific insights

    View All

    23andMe Reports Second Quarter Fiscal Year 2025 Financial Results

    SUNNYVALE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME), a leading human genetics and preventive health company, reported its financial results for the second quarter of fiscal year 2025 (FY25), which ended September 30, 2024. Key Results: Improved GAAP Net Loss by 21% and Adjusted EBITDA by 26% for the same period in the prior year (see important additional information below).The 23andMe comprehensive Total Health longevity service is now available to all customers, combining whole exome genetic sequencing with bi-annual lab tests for 55+ key blood biomarkers, and expert clinicians trained in genetics-informed preventive care and health action p

    11/12/24 7:30:00 AM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CORRECTION - 23andMe to Report Q2 FY2025 Financial Results

    SUNNYVALE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- An earlier release under the same headline should have noted 23andMe Holding Co. (NASDAQ:ME) (23andMe) will report financial results for the second quarter of fiscal year 2025 (FY2025) prior to the market opening on Tuesday, November 12, 2024 (the prior release incorrectly stated the results would be reported after the market closes). The Company will webcast a conference call at 8:00 a.m. Eastern Time on that date to discuss the quarter's results and report on business progress. The webcast can be accessed on the day of the event at this link. A webcast replay will be available at the same address following the event. In addition, 23

    11/7/24 5:54:12 PM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    23andMe to Report Q2 FY2025 Financial Results

    SUNNYVALE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) (23andMe), a leading human genetics and biopharmaceutical company, announced today that it will report financial results for the second quarter of fiscal year 2025 (FY2025) after the market closes on Tuesday, November 12, 2024. The Company will webcast a conference call at 4:30 p.m. Eastern Time on that date to discuss the quarter's results and report on business progress. The webcast can be accessed on the day of the event at this link. A webcast replay will be available at the same address following the event. In addition, 23andMe will use the Say Technologies platform to allow retail and institutional

    11/7/24 7:30:00 AM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ME
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by 23andMe Holding Co.

    SC 13D/A - 23andMe Holding Co. (0001804591) (Subject)

    11/15/24 4:48:20 PM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by 23andMe Holding Co.

    SC 13D/A - 23andMe Holding Co. (0001804591) (Subject)

    11/15/24 4:20:24 PM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by 23andMe Holding Co.

    SC 13G - 23andMe Holding Co. (0001804591) (Subject)

    11/13/24 6:00:29 AM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ME
    Leadership Updates

    Live Leadership Updates

    View All

    23andMe Appoints Three New Independent Directors to Board

    SUNNYVALE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) (the "Company" or "23andMe"), a leading human genetics and preventive health company, today announced the appointments of Andre Fernandez, Jim Frankola, and Mark Jensen, three accomplished and experienced executives, as independent members of the Company's Board of Directors (the "Board"), effective on October 28, 2024. Each of Mr. Fernandez, Mr. Frankola, and Mr. Jensen have been appointed to serve as members of the Board's Audit Committee and Compensation Committee, with Mr. Fernandez serving as the Chair of the Audit Committee and Mr. Jensen serving as the Chair of the Compensation Committee. In additio

    10/29/24 7:30:00 AM ET
    $ANSS
    $CDLX
    $LSCC
    Computer Software: Prepackaged Software
    Technology
    Computer Software: Programming Data Processing
    Semiconductors

    Madryn Asset Management, a Top Shareholder of SomaLogic, Issues Letter Regarding Opposition to the Company's Proposed Merger with Standard BioTools

    Files Preliminary Proxy Statement to Solicit Shareholders to Oppose the Merger Intends to Vote AGAINST the Conflict-Plagued and Excessively Dilutive Transaction, Which Stands to Unduly Benefit Certain Investors and Standard BioTools at the Expense of SomaLogic's Shareholders Notes the Current Premium for SomaLogic Shareholders, Based on the Deal's Exchange Ratio and Standard BioTools' Trading Price, is Only ~4.3% Underscores That SomaLogic Has Superior Alternatives to a Flawed Combination, Including a Standalone Path Leveraging its Considerable Cash Position and Strong Balance Sheet Madryn Asset Management, LP (collectively with its affiliates, "Madryn"), a holder of approximately 4

    12/12/23 5:31:00 PM ET
    $EXAS
    $ILMN
    $LAB
    Medical Specialities
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Reza Afkhami Joins 23andMe as Chief Corporate Development Officer

    SOUTH SAN FRANCISCO, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) ("23andMe"), a leading human genetics and biopharmaceutical company, today announced the appointment of Reza Afkhami as its Chief Corporate Development Officer overseeing corporate development efforts across its therapeutics, research services and consumer groups. Afkhami will be responsible for spearheading and driving a wide range of industry collaborations for the Company. 23andMe Therapeutics has a pipeline of genetically validated discovery and clinical programs, which it intends to advance through collaborations with pharmaceutical companies. Furthermore, 23andMe hopes to help the pharmac

    5/8/23 7:00:00 AM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care